Jubilant Ingrevia Reports Strong Q2 FY26 Growth Momentum

Specialty Chemicals lead growth with robust revenue gains; company posts 18% rise in profit after tax.

Jubilant Ingrevia Limited announced its financial results for the quarter ended September 30, 2025, reflecting consistent operational growth driven by its Specialty Chemicals and Nutrition segments. Despite ongoing challenges in global chemical markets, the company reported solid improvements in revenue, EBITDA, and profitability, underscoring its strategic progress and resilience.

The Board of Jubilant Ingrevia Limited met today to review and approve the company’s unaudited financial results for the second quarter of FY26.

Commenting on the results, Mr. Shyam S Bhartia, Chairman, and Mr. Hari S Bhartia, Co-Chairman, stated:

“We are pleased to present another quarter of steady performance. Our Specialty Chemicals division continues to lead growth, recording double-digit year-on-year revenue expansion and sequential improvement over the previous quarter. The Nutrition business also maintained consistent volume growth across both core product lines, while the Chemical Intermediates segment achieved its highest quarterly sales in six quarters, both in terms of value and volume.

Despite global market headwinds, we sustained revenue growth through higher market share and volumes while maintaining profitability. This quarter, our EBITDA increased by 8% YoY, and Profit After Tax rose 18% YoY. On a half-yearly basis, EBITDA expanded by 18%, and PAT surged 34%, reflecting the effectiveness of our strategy and disciplined execution.”

Markets Update:

Across the global chemical industry, demand recovery remains steady even as pricing pressure continues across multiple categories. In contrast, several international players, particularly in Europe, are facing weakened financial performance due to lower demand and elevated energy costs.

The pharmaceutical end-use market continues to exhibit consistent volume growth with stable pricing, supported by strong momentum in CDMO and Fine Chemicals. The Paracetamol segment also witnessed marginal recovery in demand during the quarter.

In the Agrochemicals sector, the post-inventory destocking phase has transitioned into growth, with volumes showing clear improvement on both year-on-year and quarter-on-quarter bases. Pricing has remained stable over recent quarters, signaling continued market normalization.

The Nutrition business posted steady volume growth. Although feed-grade vitamin prices fluctuated globally and domestically, Niacinamide demand showed modest recovery as customer buying activity improved. Choline volumes, which typically decline in Q2 due to seasonal factors, registered a year-on-year increase, underscoring stronger market fundamentals.

Future Outlook:

Looking ahead to the second half of FY26, Jubilant Ingrevia expects continued positive momentum, driven by growth in the Specialty Chemicals and Nutrition segments, alongside partial recovery in the Acetyls portfolio.

“We are on track to commence deliveries for a major CDMO contract in early 2026, which will further strengthen our growth trajectory in this high-potential segment. To support this expansion, construction has begun on a new multi-purpose plant (MPP) in Gajraula, scheduled for completion by late 2026,” the management added.

Providing additional insights, Mr. Deepak Jain, CEO & Managing Director, Jubilant Ingrevia Limited, remarked:

“Over the past year, we have made significant progress across all pillars of value creation, both for the short and long term. This progress is evident in our Q2 results — marked by strong growth in Specialty and Nutrition, stable EBITDA, and an expanding pipeline of new opportunities. As part of our ‘Pinnacle’ transformation journey, we continue to achieve new milestones that reinforce our commitment to sustainable growth and long-term value for stakeholders.”